EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections ...
How does recurrent C difficile infection impact health care resources utilization and other medical costs? What are the ways in which recurrent C difficile infection can adversely impact a patient ...
No reason was provided for the discontinuation. Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback